# The Optimal Treatment for Treatment-resistant Schizophrenia

> **NCT02926976** · NA · UNKNOWN · sponsor: **Shanghai Mental Health Center** · enrollment: 150 (estimated)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Risperidone with Clozapine
- **DRUG:** Aripiprazole with Clozapine
- **DRUG:** sodium valproate with Clozapine
- **DEVICE:** modified electroconvulsive therapy(MECT) with Clozapine
- **DEVICE:** Magnetic seizure therapy(MST) with Clozapine
- **DEVICE:** clozapine

## Key facts

- **NCT ID:** NCT02926976
- **Lead sponsor:** Shanghai Mental Health Center
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-11
- **Primary completion:** 2019-09
- **Final completion:** 2019-09
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2019-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02926976

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02926976, "The Optimal Treatment for Treatment-resistant Schizophrenia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02926976. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*